Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.40 |
| ▸ | HTR3B | O95264 | 3/20 | 0.40 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610464 | 1.00 | PNMT (0.62) | PNMTTAAR1AOC3CYP3A4IDO1 | |
| SCHEMBL21610466 | 1.00 | PNMT (0.62) | PNMTTAAR1AOC3CYP3A4IDO1 | |
| SCHEMBL23750242 | 0.81 | PNMT (0.57) | PNMTTAAR1AOC3CYP3A4IDO1 | |
| SCHEMBL21610469 | 0.79 | TAAR1 (0.52) | TAAR1 | |
| SCHEMBL21610477 | 0.79 | TAAR1 (0.52) | TAAR1 | |
| SCHEMBL21610472 | 0.79 | TAAR1 (0.52) | TAAR1 | |
| SCHEMBL777207 | 0.79 | PNMT (0.74) | PNMTTAAR1AOC3CYP3A4IDO1 | |
| SCHEMBL13302617 | 0.78 | PNMT (0.62) | PNMTTAAR1AOC3CYP3A4IDO1 | |
| SCHEMBL23750225 | 0.78 | PNMT (0.54) | PNMTTAAR1TSHRRECQLHTR3E | |
| SCHEMBL23750218 | 0.78 | PNMT (0.54) | PNMTTAAR1TSHRRECQLHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20210246169-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| WO-2020002325-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012121-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPL21 | PNMT 1771/4885TAAR1 2003/4885AOC3 3958/4885 |
| US-20210246169-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPS35 | PNMT 1862/4885TAAR1 1982/4885AOC3 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.